Windtree Therapeutics Inc /De/

Windtree Therapeutics is a U.S.-based biotechnology company focused on developing therapies for cardiovascular disease, hypertension, and oncology. Its portfolio includes istaroxime, rostafuroxin, preclinical SERCA2a activators, and an aPKCi inhibitor, alongside licensing arrangements and product-candidate partnerships.

0.45

0.45

— Windtree Therapeutics Inc /De/
%
Cardiovascular drug candidates45% Therapies aimed at acute heart failure, cardiogenic shock, and related cardiovascular conditions.
Hypertension drug candidates15% Genetically targeted treatment programs for specific hypertension patient populations.
Oncology preclinical programs15% Early-stage inhibitor programs being explored for rare and broad oncology indications.
Licensing and collaboration revenue25% Out-licensed programs and partnership arrangements that can generate non-product revenue.

Windtree’s direct customers are primarily pharmaceutical and biotechnology partners, licensees, and potential acquirers...

  • Biopharmaceutical partnersprimary

    License or collaborate on drug candidates and development programs to share risk and advance assets.

  • Acquisition targets / subsidiary buyersprimary

    Companies or assets with FDA-approved products that can be acquired to build revenue-generating subsidiaries.

  • Healthcare providerssecondary

    Hospitals and physicians that would use approved cardiovascular therapies in acute care settings.

  • Specialty treatment populationssecondary

    Patients with genetically defined hypertension or oncology indications targeted by specific programs.

Windtree is headquartered in the United States and operates as a U.S.-based development-stage biotech company...

  • •Headquartered in the United States
  • •Primary operations are U.S.-based R&D and corporate activities
  • •Potential collaborations may target specified geographic markets
  • •No country-level revenue disclosure in provided excerpts
  • •Commercial reach depends on partner licensing and approvals

Windtree’s strategy is to advance its cardiovascular and oncology pipeline while building a revenue-generating platform...

01
Advance cardiovascular pipeline assetsmedium-term

Clinical progress is needed to create value in the core development portfolio.

02
Acquire revenue-generating subsidiariesshort-term

FDA-approved products can provide commercial revenue while the pipeline matures.

03
Secure partnerships and licensing dealsshort-term

Collaborations can provide funding, market access, and development support.

Windtree faces the typical risks of a development-stage biotech company: clinical failure, regulatory setbacks, and...

critical

Going concern and near-term funding risk

The company needs additional capital to finance operations and development activities.

Scope
Corporate liquidity and continuity of R&D
Materiality
high
high

Clinical and regulatory development risk

Drug candidates may fail in trials or not obtain required approvals.

Scope
Istaroxime, rostafuroxin, SERCA2a, aPKCi programs
Materiality
high
high

Nasdaq listing compliance risk

Failure to meet continued listing requirements can lead to delisting.

Scope
Common stock trading and capital access
Materiality
high
high

Intangible asset impairment risk

IPR&D values depend on future commercial success and development assumptions.

Scope
Istaroxime and rostafuroxin intangible assets
Materiality
high
Indefinite-lived IPR&D intangible assets
Can create material impairment charges if prospects weaken
Fair value measurement of financing instruments
Can affect reported earnings and equity balances
Preferred stock accretion and deemed dividends
Reduces earnings available to common shareholders
Going-concern assessment
Influences disclosure and investor assessment of solvency risk

Dyne Therapeutics, Inc.

DYN · Pharmaceutical Preparations

Inhibitor Therapeutics, Inc.

INTI · Pharmaceutical Preparations

TherapeuticsMD, Inc.

TXMD · Pharmaceutical Preparations

INTENSITY THERAPEUTICS, INC.

INTS · Biological Products, (No Diagnostic Substances)

AIM ImmunoTech Inc.

AIM · Biological Products, (No Diagnostic Substances)

OS Therapies Inc

OSTX · Pharmaceutical Preparations

: 29.4.2026